Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VVD-214 + bevacizumab
- Development stage
- Phase 1
- Lead developer
- Vividion Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
VVD-214 + bevacizumab is an investigational combination therapy being evaluated for the treatment of advanced microsatellite instability-high (MSI-high) or deficient mismatch repair (dMMR) colorectal cancer. VVD-214 (also known as RO7589831 or VVD-133214) is an oral, small-molecule, covalent allosteric inhibitor of Werner helicase (WRN), a DNA repair enzyme that represents a synthetic lethal target in MSI-high or dMMR cancers. Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and tumor vascularization. The combination is being evaluated in a Phase 1b clinical trial (NCT06004245) in patients with previously treated advanced MSI-high or dMMR colorectal cancer.
- Other names
- RO7589831 + AvastinRO7589831 + bevacizumabVVD-133214 + AvastinVVD-133214 + bevacizumabVVD-214 + AvastinVVD-214 + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)WRN (Werner syndrome ATP-dependent helicase)
Beyond the preview
Go deeper on VVD-214 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VVD-214 + bevacizumab.